Tau enhances α-synuclein aggregation and toxicity in cellular models of synucleinopathy
- PMID: 22039514
- PMCID: PMC3200341
- DOI: 10.1371/journal.pone.0026609
Tau enhances α-synuclein aggregation and toxicity in cellular models of synucleinopathy
Abstract
Background: The simultaneous accumulation of different misfolded proteins in the central nervous system is a common feature in many neurodegenerative diseases. In most cases, co-occurrence of abnormal deposited proteins is observed in different brain regions and cell populations, but, in some instances, the proteins can be found in the same cellular aggregates. Co-occurrence of tau and α-synuclein (α-syn) aggregates has been described in neurodegenerative disorders with primary deposition of α-syn, such as Parkinson's disease and dementia with Lewy bodies. Although it is known that tau and α-syn have pathological synergistic effects on their mutual fibrillization, the underlying biological effects remain unclear.
Methodology/principal findings: We used different cell models of synucleinopathy to investigate the effects of tau on α-syn aggregation. Using confocal microscopy and FRET-based techniques we observed that tau colocalized and interacted with α-syn aggregates. We also found that tau overexpression changed the pattern of α-syn aggregation, reducing the size and increasing the number of aggregates. This shift was accompanied by an increase in the levels of insoluble α-syn. Furthermore, co-transfection of tau increased secreted α-syn and cytotoxicity.
Conclusions/significance: Our data suggest that tau enhances α-syn aggregation and toxicity and disrupts α-syn inclusion formation. This pathological synergistic effect between tau and α-syn may amplify the deleterious process and spread the damage in neurodegenerative diseases that show co-occurrence of both pathologies.
Conflict of interest statement
Figures
Similar articles
-
Dual Targeting of Monomeric Tau and α-Synuclein Aggregation: A New Multitarget Therapeutic Strategy for Neurodegeneration.ACS Chem Neurosci. 2020 Jul 15;11(14):2051-2057. doi: 10.1021/acschemneuro.0c00281. Epub 2020 Jun 29. ACS Chem Neurosci. 2020. PMID: 32579329
-
Structural basis of the interplay between α-synuclein and Tau in regulating pathological amyloid aggregation.J Biol Chem. 2020 May 22;295(21):7470-7480. doi: 10.1074/jbc.RA119.012284. Epub 2020 Apr 13. J Biol Chem. 2020. PMID: 32291284 Free PMC article.
-
Associations Between APOE Variants, Tau and α-Synuclein.Adv Exp Med Biol. 2019;1184:177-186. doi: 10.1007/978-981-32-9358-8_15. Adv Exp Med Biol. 2019. PMID: 32096038 Review.
-
Polymorphic α-Synuclein Strains Modified by Dopamine and Docosahexaenoic Acid Interact Differentially with Tau Protein.Mol Neurobiol. 2020 Jun;57(6):2741-2765. doi: 10.1007/s12035-020-01913-6. Epub 2020 Apr 29. Mol Neurobiol. 2020. PMID: 32350746 Free PMC article.
-
The contribution of alpha synuclein to neuronal survival and function - Implications for Parkinson's disease.J Neurochem. 2016 May;137(3):331-59. doi: 10.1111/jnc.13570. Epub 2016 Mar 23. J Neurochem. 2016. PMID: 26852372 Free PMC article. Review.
Cited by
-
Prevalence, distribution, and severity of cerebral amyloid angiopathy differ between Lewy body diseases and Alzheimer's disease.Acta Neuropathol Commun. 2024 Feb 15;12(1):28. doi: 10.1186/s40478-023-01714-7. Acta Neuropathol Commun. 2024. PMID: 38360761 Free PMC article.
-
Distinct tau and alpha-synuclein molecular signatures in Alzheimer's disease with and without Lewy bodies and Parkinson's disease with dementia.Acta Neuropathol. 2024 Jan 10;147(1):14. doi: 10.1007/s00401-023-02657-y. Acta Neuropathol. 2024. PMID: 38198008 Free PMC article.
-
Prevalence of Concomitant Pathologies in Parkinson's Disease: Implications for Prognosis, Diagnosis, and Insights into Common Pathogenic Mechanisms.J Parkinsons Dis. 2024;14(1):35-52. doi: 10.3233/JPD-230154. J Parkinsons Dis. 2024. PMID: 38143370 Free PMC article. Review.
-
USP19 deubiquitinase inactivation regulates α-synuclein ubiquitination and inhibits accumulation of Lewy body-like aggregates in mice.NPJ Parkinsons Dis. 2023 Nov 28;9(1):157. doi: 10.1038/s41531-023-00601-1. NPJ Parkinsons Dis. 2023. PMID: 38017009 Free PMC article.
-
Nigrostriatal tau pathology in parkinsonism and Parkinson's disease.Brain. 2024 Feb 1;147(2):444-457. doi: 10.1093/brain/awad388. Brain. 2024. PMID: 38006313 Free PMC article.
References
-
- Chartier-Harlin MC, Kachergus J, Roumier C, Mouroux V, Douay X, et al. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet. 2004;364:1167–1169. - PubMed
-
- Ibanez P, Bonnet AM, Debarges B, Lohmann E, Tison F, et al. Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet. 2004;364:1169–1171. - PubMed
-
- Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet. 1998;18:106–108. - PubMed
-
- Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science. 1997;276:2045–2047. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
